Tags

Type your tag names separated by a space and hit enter

Development of nonhuman adenoviruses as vaccine vectors.
Vaccine. 2006 Feb 13; 24(7):849-62.V

Abstract

Human adenoviral (HAd) vectors have demonstrated great potential as vaccine vectors. Preclinical and clinical studies have demonstrated the feasibility of vector design, robust antigen expression and protective immunity using this system. However, clinical use of adenoviral vectors for vaccine purposes is anticipated to be limited by vector immunity that is either preexisting or develops rapidly following the first inoculation with adenoviral vectors. Vector immunity inactivates the vector particles and rapidly removes the transduced cells, thereby limiting the duration of transgene expression. Due to strong vector immunity, subsequent use of the same vector is usually less efficient. In order to circumvent this limitation, nonhuman adenoviral vectors have been proposed as alternative vectors. In addition to eluding HAd immunity, these vectors possess most of the attractive features of HAd vectors. Several replication-competent or replication-defective nonhuman adenoviral vectors have been developed and investigated for their potential as vaccine-delivery vectors. Here, we review recent advances in the design and characterization of various nonhuman adenoviral vectors, and discuss their potential applications for human and animal vaccination.

Authors+Show Affiliations

Laboratory of Gene Therapy, Department of Veterinary Pathobiology, Purdue University, West Lafayette, IN 47907, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

16297508

Citation

Bangari, Dinesh S., and Suresh K. Mittal. "Development of Nonhuman Adenoviruses as Vaccine Vectors." Vaccine, vol. 24, no. 7, 2006, pp. 849-62.
Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine. 2006;24(7):849-62.
Bangari, D. S., & Mittal, S. K. (2006). Development of nonhuman adenoviruses as vaccine vectors. Vaccine, 24(7), 849-62.
Bangari DS, Mittal SK. Development of Nonhuman Adenoviruses as Vaccine Vectors. Vaccine. 2006 Feb 13;24(7):849-62. PubMed PMID: 16297508.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of nonhuman adenoviruses as vaccine vectors. AU - Bangari,Dinesh S, AU - Mittal,Suresh K, Y1 - 2005/09/23/ PY - 2005/05/19/received PY - 2005/07/29/revised PY - 2005/08/25/accepted PY - 2005/11/22/pubmed PY - 2006/3/31/medline PY - 2005/11/22/entrez SP - 849 EP - 62 JF - Vaccine JO - Vaccine VL - 24 IS - 7 N2 - Human adenoviral (HAd) vectors have demonstrated great potential as vaccine vectors. Preclinical and clinical studies have demonstrated the feasibility of vector design, robust antigen expression and protective immunity using this system. However, clinical use of adenoviral vectors for vaccine purposes is anticipated to be limited by vector immunity that is either preexisting or develops rapidly following the first inoculation with adenoviral vectors. Vector immunity inactivates the vector particles and rapidly removes the transduced cells, thereby limiting the duration of transgene expression. Due to strong vector immunity, subsequent use of the same vector is usually less efficient. In order to circumvent this limitation, nonhuman adenoviral vectors have been proposed as alternative vectors. In addition to eluding HAd immunity, these vectors possess most of the attractive features of HAd vectors. Several replication-competent or replication-defective nonhuman adenoviral vectors have been developed and investigated for their potential as vaccine-delivery vectors. Here, we review recent advances in the design and characterization of various nonhuman adenoviral vectors, and discuss their potential applications for human and animal vaccination. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/16297508/Development_of_nonhuman_adenoviruses_as_vaccine_vectors_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(05)00915-1 DB - PRIME DP - Unbound Medicine ER -